Carboxy methyl cellulose

PreclinicalSmall molecule

MMinia University

Carboxy methyl cellulose is one of 9 small molecule programs targeting Corneal Ulcer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Corneal UlcerActive, not recruiting

Corneal UlcerPreclinical

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Corneal Ulcer

#DrugCompanyPhaseTrials

Levaquin

WWim Janssens

Approved

—2

Antibiotics

MMelinta Therapeutics, Inc.

Approved

1 3

Betadine

BBecton, Dickinson and Company

Phase 2

1 4

Vfend

PPrism Pharmaceuticals

Phase 2

1 5

Natacyn

HHarrow Inc

Phase 3

2 6

Riboflavin

CCornea and Laser Eye Institute

Phase 1

—7

Naltrexone Hydrochloride

EEnsysce Biosciences

Preclinical

1 8

Carboxy methyl cellulose

MMinia University

Preclinical

1 9

Specific Treatment

AAssistance Publique - Hôpitaux de Paris

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Corneal Ulcer1 trial

The Use of Naltrexone Hydrochloride to Promote Healing in Patients With Resistant Non-infectious Corneal Ulcer

Completed·MMinia University·N/A·NCT05924893·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Carboxy methyl cellulose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboxy methyl cellulose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboxy methyl cellulose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Minia University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMinia University

Carboxy methyl cellulose

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Corneal Ulcer1 trial

References

Drug Info

Quick Facts

Related News